A novel, stable, aqueous Glucagon formulation using Ferulic acid as an Excipient

Journal of Diabetes Science and Technology

Volumn 9, Issue 1, 2015, Pages 17-23

  Bakhtiani, Parkash A ^a   Caputo, Nicholas ^a   Castle, Jessica R ^a   Youssef, Joseph El ^a   Carroll, Julie M ^b   David, Larry L ^a   Roberts, Charles T ^b   Kenneth, Ward ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

closed loop system; ferulic acid; glucagon; hypoglycemia; type 1 diabetes mellitus

Indexed keywords

CURCUMIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXCIPIENT; FERULIC ACID; GLUCAGON; GLYCINE; HUMAN SERUM ALBUMIN; METHIONINE; OCTREOTIDE; POLYSORBATE 80; COUMARIC ACID; GLUCOSE BLOOD LEVEL; SOLUTION AND SOLUBILITY; WATER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BIOASSAY; CELL ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; EC50; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; TRANSMISSION ELECTRON MICROSCOPY; YORKSHIRE PIG; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; INFUSION PUMP; METABOLISM; PATHOLOGY; PHARMACOKINETICS; PIG; PROCEDURES; SOLUTION AND SOLUBILITY;

ANIMALS; BLOOD GLUCOSE; COUMARIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; GLUCAGON; HUMANS; INFUSION PUMPS; PHARMACEUTICAL SOLUTIONS; SWINE; WATER;

EID: 84942809679     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814552476     Document Type: Article

References (35)

1. Del Favero S, Bruttomesso D, Di Palma F, et al. First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care. 2014;37(5):1212-1215.
2. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: A freeliving, randomized clinical trial. Diabetes Care. 2014;37(5): 1204-1211.
3. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care. 2013;36(7):1851-1858.
4. Buckingham BA, Cameron F, Calhoun P, et al. Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther. 2013;15(8):622-627.
5. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9):2230-2237.
6. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27ra.
7. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-1287.
8. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: A randomized crossover controlled trial. CMAJ. 2013;185:297-305.
9. van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, Devries JH. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther. 2014;16:131-136.
10. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
11. Andersen CB, Otzen D, Christiansen G, Rischel C. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry. 2007;46(24):7314-7324.
12. Beaven GH, Gratzer WB, Davies HG. Formation and structure of gels and fibrils from glucagon. Eur J Biochem. 1969;11(1):37-42.
13. Onoue S, Ohshima K, Debari K, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloi-dogenic fibrils. Pharm Res. 2004;21(7):1274-1283.
14. Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol. 2010;4(6):1357-1367.
15. Ward WK, Massoud RG, Szybala CJ, et al. In vitro and in vivo evaluation of native glucagon and glucagon analog (MARD28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol. 2010;4(6): 1311-1321.
16. Joshi AB, Rus E, Kirsch LE. The degradation pathways of glucagon in acidic solutions. Int J Pharm. 2000;203(1-2):115-125.
17. Caputo N, Castle JR, Bergstrom CP, et al. Mechanisms of glucagon degradation at alkaline pH. Peptides. 2013;45:40-47.
18. Caputo N, Jackson MA, Castle JR, et al. Biochemical stabilization of glucagon at alkaline pH [published online ahead of print June 26, 2014]. Diabetes Technol Ther.
19. Shen L, Ji H-F. Low stability remedies the low bioavailability of curcumin. Trends Mol Med. 2012;18(7):363-364.
20. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867-1876.
21. Gordon ON, Schneider C. Vanillin and ferulic acid: not the major degradation products of curcumin. Trends Mol Med. 2012;18(7):361-363; author reply 3-4.
22. Ono K, Hirohata M, Yamada M. Ferulic acid destabilizes preformed beta-Amyloid fibrils in vitro. Biochem Biophys Res Commun. 2005;336(2):444-449.
23. Sgarbossa A, Monti S, Lenci F, Bramanti E, Bizzarri R, Barone V. The effects of ferulic acid on beta-Amyloid fibrillar structures investigated through experimental and computation-nal techniques. Biochimica et biophysica acta. 2013;1830(4):2924-2937.
24. DArchivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Annali dellIstituto superiore di sanita. 2007;43(4):348-361.
25. Rechner AR, Pannala AS, Rice-Evans CA. Caffeic acid derivatives in artichoke extract are metabolised to phenolic acids in vivo. Free Radic Res. 2001;35(2):195-202.
26. Bourne LC, Rice-Evans C. Bioavailability of ferulic acid. Biochem Biophys Res Commun. 1998;253(2):222-227.
27. Mancuso C, Santangelo R. Ferulic acid: Pharmacological and toxicological aspects. Food Chem Toxicol. 2014;65C:185-195.
28. Janicke B, Hegardt C, Krogh M, et al. The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer. 2011;63(4):611-622.
29. Jayaprakasam B, Vanisree M, Zhang Y, Dewitt DL, Nair MG. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. Journal of agricultural and food chemistry. J Agric Food Chem. 2006;54(15):5375-5381.
30. Suzuki A, Kagawa D, Fujii A, Ochiai R, Tokimitsu I, Saito I. Short-And long-Term effects of ferulic acid on blood pressure in spontaneously hypertensive rats. Am J Hypertens. 2002;15(4 pt 1):351-357.
31. Suzuki A, Yamamoto M, Jokura H, et al. Ferulic acid restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats. Am J Hypertens. 2007;20(5):508-513.
32. USP Organization; United States Pharmacopoeia (USP 36-NF 31). May 1, 2013:3741-2.
33. Jackson M, Stonex T, Caputo N, et al. Development of a stable formulation of liquid glucagon for use in a bihormonal pump. Paper presented at: 2012 Scientific Session, American Diabetes Association; Philadelphia, PA.
34. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006;355(3):501-523.
35. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. Optimization of the native glucagon sequence for medicinal purposes. J Diabetes Sci Technol. 2010;4(6):1322-1331.